MedImmune (MDI.L), the global biologics arm of AstraZeneca (AZN,AZN.L), announced it has signed an in-licensing agreement with Progenics Pharmaceuticals, Inc. (PGNX) for Progenics' Clostridium difficile late-stage preclinical program. The agreement was led by MedImmune's Infectious Diseases & Vaccines Innovative Medicines Unit.
MedImmune's program will assess the potential efficacy and safety of treatment of the infection with investigational monoclonal antibodies targeting toxins that mediate the disease.
Financial details of the agreement were not disclosed.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.